Hesham Mohamed

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

Elias Jabbour, Hagop M. Kantarjian, Giuseppe Saglio et al. · Blood · 2013 · 390 citations · Full text

Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study

Neil P. Shah, François Guilhot, Jörge E. Cortes et al. · Blood · 2014 · 194 citations

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034

Neil P. Shah, Philippe Rousselot, Charles A. Schiffer et al. · American Journal of Hematology · 2016 · 180 citations · Full text

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial

Justin M. Watts, Maria R. Baer, Jay Yang et al. · The Lancet Haematology · 2022 · 111 citations · Full text

Phase 1/2, Hematological Malignancy, Myelodysplastic Syndrome +9

Olutasidenib (FT-2102) in patients with relapsed or refractory <i>IDH1</i>-mutant glioma: A multicenter, open-label, phase Ib/II trial

Macarena I. de la Fuente, Howard Colman, Mark Rosenthal et al. · Neuro-Oncology · 2022 · 65 citations · Full text